Royalty Pharma PLC (RPRX) Social Stream
ROYALTY PHARMA PLC (RPRX) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering RPRX.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-10 | 8 | $56.001 | $46 | $51.714 | $32.38 | 59.71% |
| 2022-02-02 | 7 | $56 | $46 | $51.714 | $32.38 | 59.71% |
| 2022-03-08 | 7 | $56 | $46 | $51.142 | $32.38 | 57.94% |
| 2022-04-06 | 7 | $56 | $48 | $51.428 | $32.38 | 58.83% |
| 2022-05-06 | 7 | $56 | $48 | $51.428 | $32.38 | 58.83% |
| 2022-06-09 | 9 | $56 | $48 | $52.111 | $32.38 | 60.94% |
| 2022-06-14 | 10 | $56 | $47 | $51.6 | $32.38 | 59.36% |
| 2022-08-03 | 10 | $57 | $47 | $52.3 | $32.38 | 61.52% |
| 2022-10-12 | 10 | $57 | $47 | $52.6 | $32.38 | 62.45% |
| 2022-10-27 | 10 | $57 | $47 | $52.8 | $32.38 | 63.06% |
| 2022-11-28 | 9 | $57 | $47 | $53.111 | $32.38 | 64.02% |
| 2022-12-06 | 9 | $57 | $47 | $52.777 | $32.38 | 62.99% |
| 2023-02-15 | 9 | $57 | $47 | $52 | $32.38 | 60.59% |
| 2023-03-29 | 9 | $57 | $47 | $52.111 | $32.38 | 60.94% |
| 2023-04-10 | 9 | $57 | $47 | $52.333 | $32.38 | 61.62% |
| 2023-04-21 | 9 | $60 | $42 | $50.625 | $32.38 | 56.35% |
| 2023-05-10 | 8 | $60 | $42 | $50.25 | $32.38 | 55.19% |
The Trend in the Analyst Price Target
Over the past 15 months, RPRX's average price target has gone down $1.29.
Over the past 48 weeks, RPRX's average upside potential has been 32.94%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-06-14 | 10 | 56 | 47 | 51.600 | 38.20 | 35.08% |
| 2022-08-05 | 10 | 57 | 47 | 52.600 | 42.45 | 23.91% |
| 2023-01-25 | 9 | 57 | 47 | 52.333 | 38.72 | 35.16% |
| 2023-01-27 | 9 | 57 | 47 | 52.333 | 38.90 | 34.53% |
| 2023-04-21 | 9 | 60 | 42 | 51.222 | 36.10 | 41.89% |
RPRX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.19 | 6 | 2 | 0 | 0 | 0 | 8 |
The Trend in the Broker Recommendations
Over the past 151 days, RPRX's average broker recommendation rating worsened by 0.03.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of all US stocks, ROYALTY PHARMA PLC's variance in analysts' estimates is lower than -371.66% of them.
- To contextualize these metrics, consider that out of stocks in the large market cap category, ROYALTY PHARMA PLC's number of analysts covering the stock is higher than 434.55% of them.
- RPRX has a higher upside potential (average analyst target price relative to current price) than 1568.53% of stocks in the large market cap category.
- RPRX has a higher average analyst price target than 1473.85% of Pharmaceutical Products stocks.
In the Pharmaceutical Products industry, CVAC, MRVI, and ABCL are the three stocks most similar to ROYALTY PHARMA PLC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is RPRX a Buy, Hold or Sell? See the POWR Ratings now!